Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiemetic agents.

H Bleiberg1

  • 1Institut Jules Bordet, Brussels, Belgium.

Current Opinion in Oncology
|August 1, 1992
PubMed
Summary
This summary is machine-generated.

Chemotherapy-induced emesis remains a challenge, with current antiemetics offering limited control for delayed nausea and vomiting. Combination therapy shows promise for highly emetogenic chemotherapy, but standard antiemetics may suffice for moderate regimens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.

Acta gastro-enterologica Belgica·2012
Same author

Differential diagnosis of adnexal masses: sequential use of the risk of malignancy index and HistoScanning, a novel computer-aided diagnostic tool.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2011
Same author

Cost-effectiveness of cetuximab in combination with irinotecan compared with current care in metastatic colorectal cancer after failure on irinotecan--a Belgian analysis.

Acta clinica Belgica·2008
Same author

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.

Annals of oncology : official journal of the European Society for Medical Oncology·2007
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Therapeutics

Background:

  • Chemotherapy-induced emesis (CIE) affects a significant portion of patients, particularly those on cisplatin-based regimens.
  • Despite advancements, controlling acute, delayed, and anticipatory emesis remains an unmet clinical need.
  • Current antiemetic strategies show varying efficacy depending on chemotherapy emetogenicity.

Purpose of the Study:

  • To evaluate the efficacy of antiemetic regimens for chemotherapy-induced emesis.
  • To compare combination therapy versus monotherapy for highly and moderately emetogenic chemotherapy.
  • To assess treatment options for delayed and anticipatory emesis.

Main Methods:

  • Review of clinical studies on antiemetic therapies for cisplatin-based chemotherapy.

Related Experiment Videos

  • Comparison of ondansetron, dexamethasone, and metoclopramide efficacy.
  • Analysis of treatment outcomes for acute, delayed, and anticipatory emesis.

    • Main Results:

    • Combination of ondansetron and dexamethasone is superior to dexamethasone alone for highly emetogenic chemotherapy.
    • Standard antiemetics achieve comparable control to ondansetron for moderately emetogenic regimens.
    • Delayed emesis shows poor control, with no significant difference between metoclopramide, dexamethasone, ondansetron, and placebo.

    Conclusions:

    • Ondansetron may be limited in moderately emetogenic regimens to reduce costs, reserved for cases of standard therapy failure.
    • Further research is needed to confirm the efficacy of ondansetron and dexamethasone combination for delayed emesis.
    • Optimizing antiemetic strategies is crucial for improving patient quality of life during chemotherapy.